Sign Out
Omexac-40: Nelfinavir, atazanavir: The plasma levels of nelfinavir and atazanavir are decreased in case of co-administration with Omeprazole.
Digoxin: Concomitant treatment with Omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10%. Digoxin toxicity has been rarely reported.
Clopidogrel: Results from studies in healthy subjects have shown a pharmacokinetic (PK)/pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and Omeprazole (80 mg p.o. daily) resulting in a decreased exposure to the active metabolite of clopidogrel by an average of 46% and a decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 16%.
Other active substances: The absorption of Posaconazole, Erlotinib, Ketoconazole and Itraconazole is significantly reduced and thus clinical efficacy may be impaired. For Posaconazole and Erlotinib concomitant use should be avoided.
